Articles

Diagnostic testing in myeloid malignancies by next-generation sequencing: recommendations from the Commission Personalised Medicine

BJH - volume 10, issue 6, october 2019

E. Van Valckenborgh PhD, M. Bakkus PhD, E. Boone PhD, A. Camboni MD, PhD, J-P. Defour PhD, B. Denys MD, H. Devos MD, L. Dewispelaere MD, G. Froyen PhD, A. Hébrant PhD, P. Heimann MD, PhD, P. Hermans MD, PhD, E. Heylen PhD, K. Jacobs PhD, F. Lambert MD, M. Le Mercier Apr, PhD, E. Lierman PhD, H. Louagie MD, PhD, B. Maes MD, PhD, M-B. Maes PhD, G. Martens MD, PhD, L. Michaux MD, PhD, F. Nollet PhD, MSc, H.A. Poirel MD, PhD, G. Raicevic PhD, P. Saussoy MD, PhD, T. Tousseyn MD, PhD, M. Van Den Bulcke PhD, P. Vandenberghe MD, PhD, K. Vandepoele PhD, P. Vannuffel PhD, T. Venken PhD, K. Vermeulen PhD

SUMMARY

Molecular diagnostics have an increasing impact on diagnosis, risk stratification and targeted treatment in haemato-oncology. In the framework of a pilot study for the implementation of next-generation sequencing in the Belgian healthcare system, the Commission of Personalised Medicine was founded to give professional and evidence-based advice on the molecular analysis in haemato-oncology. This paper describes its recommendations for NGS analysis in myeloid malignancies. In addition, the minimally required set of genes that must be analysed is defined and algorithms for molecular workflow in myeloid malignancies are proposed.

(BELG J HEMATOL 2019;10(6):241–9)

Read more

PP03 The anaphase-promoting-complex/ cyclosome: a new promising target in mantle cell lymphoma and diffuse large B cell lymphoma

BJH - volume 8, issue Abstract Book BHS, february 2017

A. Maes , E. De Smedt , K. De Veirman , dr. K. Maes , E. Menu , E. Van Valckenborgh PhD, K. Vanderkerken PhD, E. De Bruyne

Read more

PP1.2 The immunosuppressive role of the adipokine leptin in multiple myeloma

BJH - volume 7, issue Abstract Book BHS, january 2016

M. Favreau , K. Venken , E. De Bruyne , E. Van Valckenborgh PhD, dr. K. Maes , K. Vanderkerken PhD, D. Elewaut , E. Menu

Read more

P1.04 Tumor-associated macrophages induce Multiple Myeloma cell survival and STAT3 activation

BJH - volume 7, issue Abstract Book BHS, january 2016

N. De Beule MD, PhD, K. De Veirman , dr. K. Maes , E. De Bruyne , E. Menu , R. Schots MD, PhD, K. Vanderkerken PhD, E. Van Valckenborgh PhD

Read more

P1.05 Exosomal miR-146a from multiple myeloma cells regulates cytokine and chemokine secretion in mesenchymal stromal cells

BJH - volume 7, issue Abstract Book BHS, january 2016

K. De Veirman , J. Wang , S. Xu , X. Leleu , E. Himpe , dr. K. Maes , E. De Bruyne , E. Van Valckenborgh PhD, K. Vanderkerken PhD, E. Menu , I. Van Riet PhD

Read more

P1.13 Blocking S100A9 interactions in the Multiple Myeloma bone marrow environment reduces angiogenesis and tumor growth

BJH - volume 7, issue Abstract Book BHS, january 2016

E. Van Valckenborgh PhD, K. De Veirman , H. De Raeve MD, PhD, dr. K. Maes , E. De Bruyne , E. Menu , K. Vanderkerken PhD

Read more

P1.01 Myeloid Derived Suppressor Cells induce Multiple Myeloma cell survival through AMPK activation

BJH - volume 6, issue Abstract Book BHS, january 2015

K. De Veirman , J. van Ginderachter , N. De Beule MD, PhD, S. Lub , A. Maes , E. De Bruyne , E. Menu , I. Van Riet PhD, K. Vanderkerken PhD, E. Van Valckenborgh PhD

Read more
X